Overview

Bergamot extract is obtained from the fruit and peel of Citrus bergamia, a citrus tree primarily cultivated in the Calabria region of southern Italy. The extract is distinguished by its unusually high concentration of polyphenolic flavonoids, including brutieridin and melitidin, which are structurally similar to commercial statins and have been shown to inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Other bioactive flavonoids present include neoeriocitrin, naringin, and neohesperidin.

Clinical studies have demonstrated that bergamot polyphenol fractions can significantly reduce total cholesterol, LDL cholesterol, and triglycerides while modestly increasing HDL cholesterol in patients with hyperlipidemia. The lipid-lowering effects have been observed both as monotherapy and as an adjunct to low-dose statin therapy, where bergamot may allow for statin dose reduction while maintaining efficacy. Beyond lipid modulation, bergamot extract has shown effects on blood glucose metabolism, with evidence of reduced fasting glucose and improved insulin sensitivity, suggesting potential utility in metabolic syndrome management.

Bergamot supplementation is commercially available in standardized polyphenol-enriched formulations. It is generally well-tolerated, with gastrointestinal discomfort being the most commonly reported adverse effect. It should be distinguished from bergamot essential oil used in aromatherapy, which contains bergapten (a phototoxic furanocoumarin) and is not intended for internal use. While the existing clinical evidence is promising, larger multicenter trials are needed to fully establish bergamot extract's role in cardiovascular risk management.

Mechanism of Action

Unique Flavonoid Glycoside Profile

Bergamot (Citrus bergamia) polyphenol fraction contains a unique profile of statin-like flavonoid glycosides — principally neoeriocitrin, neohesperidin, and naringin — along with their aglycones and the 3-hydroxy-3-methylglutaryl (HMG) derivatives brutieridin and melitidin. These HMG-conjugated flavanones structurally mimic the HMG-CoA substrate, enabling direct competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis (PMID: 24346432).

AMPK Activation & Metabolic Regulation

Bergamot polyphenols activate AMPK in hepatocytes and adipocytes, leading to: (1) phosphorylation and inactivation of acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and derepressing CPT-1-mediated mitochondrial fatty acid oxidation, (2) suppression of SREBP-1c transcriptional activity, reducing de novo lipogenesis, and (3) enhanced glucose uptake via GLUT4 translocation. These combined effects reduce hepatic triglyceride synthesis and accumulation (PMID: 25316051).

Antioxidant & Anti-Inflammatory Pathways

Naringin and neoeriocitrin activate Nrf2-ARE signaling, upregulating phase II detoxification enzymes (HO-1, NQO1, GST) and antioxidant defenses. Simultaneously, bergamot flavonoids inhibit NF-kB and LOX/COX pathways, reducing vascular inflammation. Neohesperidin specifically suppresses VCAM-1 and ICAM-1 expression on endothelial cells, decreasing monocyte recruitment to atherosclerotic lesions (PMID: 27464876).

Cardiovascular & Hepatoprotective Effects

Clinical trials demonstrate reductions in total cholesterol (20-30%), LDL (25-35%), and triglycerides (30-40%) with bergamot extract (500-1000 mg/day). The mechanism involves enhanced hepatic LDLR expression secondary to reduced intracellular cholesterol pools, combined with AMPK-driven fatty acid oxidation that reduces VLDL assembly and secretion (PMID: 23349136).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Bergamot

Common Side Effects

• Gastrointestinal discomfort (heartburn, nausea, abdominal cramping) in ~8-12% of users
• Dizziness or lightheadedness
• Muscle cramps (possibly related to HMG-CoA reductase-like activity)
• Increased photosensitivity when bergamot oil is applied topically (contains bergapten/furanocoumarins)

Serious Adverse Effects

• Phototoxic dermatitis (berloque dermatitis) with topical use and UV exposure
• Potential QT prolongation at very high doses (theoretical, based on in vitro data)
• Rare hepatotoxicity with excessive supplementation
• Rhabdomyolysis-like symptoms reported in isolated cases (muscle pain, dark urine)

Contraindications

• Known allergy to citrus fruits or Rutaceae family plants
• Active photosensitivity disorders (e.g., porphyria, lupus with photosensitivity)
• Severe hepatic impairment
• Concurrent use of photosensitizing medications with topical bergamot application

Drug Interactions

• Statins (atorvastatin, rosuvastatin): Bergamot has statin-like HMG-CoA reductase inhibitory activity; concurrent use may increase risk of myopathy/rhabdomyolysis
• CYP3A4 substrates: Bergamot juice/extract may inhibit CYP3A4, increasing levels of drugs metabolized by this enzyme (similar to grapefruit)
• Anticoagulants (warfarin): May potentiate anticoagulant effects; monitor INR
• Antihypertensives: Additive hypotensive effects possible
• Thyroid medications (levothyroxine): May impair absorption; separate administration by 2+ hours

Population-Specific Considerations

• Pregnancy/Lactation: Insufficient safety data; avoid bergamot supplements. Topical bergamot oil should be avoided due to phototoxicity risk
• Pediatric: Not recommended; no established pediatric safety data
• Renal impairment: Use caution; limited clearance data available
• Hepatic impairment: Avoid in moderate-severe liver disease; bergamot polyphenols undergo hepatic metabolism
• Elderly: Start with lower doses; increased sensitivity to hypotensive and lipid-lowering effects

Pharmacokinetic Profile